Literature DB >> 15036875

How does Parkinson's disease begin? The role of compensatory mechanisms.

Jose A Obeso, Maria C Rodriguez-Oroz, Jose L Lanciego, Manuel Rodriguez Diaz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15036875     DOI： 10.1016/j.tins.2003.12.006

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN： 0166-2236            Impact factor:   13.837


× No keyword cloud information.
  26 in total

1.  Changes in brain functional activation during resting and locomotor states after unilateral nigrostriatal damage in rats.

Authors:  J Yang; T R Sadler; T K Givrad; J-M I Maarek; D P Holschneider
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

2.  Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.

Authors:  Xiomara A Perez; Neeraja Parameswaran; Luping Z Huang; Kathryn T O'Leary; Maryka Quik
Journal:  J Neurochem       Date:  2008-02-01       Impact factor: 5.372

3.  Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?

Authors:  Mariza Bortolanza; Fernando E Padovan-Neto; Roberta Cavalcanti-Kiwiatkoski; Maurício Dos Santos-Pereira; Miso Mitkovski; Rita Raisman-Vozari; Elaine Del-Bel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

4.  Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.

Authors:  Elaine Del-Bel; Fernando Eduardo Padovan-Neto; Raphael Escorsim Szawka; Célia Aparecida da-Silva; Rita Raisman-Vozari; Janete Anselmo-Franci; Angélica Caroline Romano-Dutra; Francisco Silveira Guimaraes
Journal:  Neurotox Res       Date:  2013-06-27       Impact factor: 3.911

Review 5.  Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex.

Authors:  Tonghui Xu; Shaofang Wang; Rupa R Lalchandani; Jun B Ding
Journal:  Mov Disord       Date:  2017-03-25       Impact factor: 10.338

Review 6.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

7.  Dopamine replacement therapy does not restore the ability of Parkinsonian patients to make rapid adjustments in motor strategies according to changing sensorimotor contexts.

Authors:  E Tunik; A G Feldman; H Poizner
Journal:  Parkinsonism Relat Disord       Date:  2007-04-18       Impact factor: 4.891

8.  Gray matter correlates of dopaminergic degeneration in Parkinson's disease: A hybrid PET/MR study using (18) F-FP-CIT.

Authors:  Hongyoon Choi; Gi Jeong Cheon; Han-Joon Kim; Seung Hong Choi; Yong-Il Kim; Keon Wook Kang; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  Hum Brain Mapp       Date:  2016-02-05       Impact factor: 5.038

9.  Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease.

Authors:  Valentina Berti; Cristina Polito; Silvia Ramat; Eleonora Vanzi; Maria Teresa De Cristofaro; Giannantonio Pellicanò; Francesco Mungai; Paolo Marini; Andreas Robert Formiconi; Sandro Sorbi; Alberto Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-02       Impact factor: 9.236

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.